198 related articles for article (PubMed ID: 22944145)
1. Diagnostic values of urine CYFRA21-1, NMP22, UBC, and FDP for the detection of bladder cancer.
Jeong S; Park Y; Cho Y; Kim YR; Kim HS
Clin Chim Acta; 2012 Dec; 414():93-100. PubMed ID: 22944145
[TBL] [Abstract][Full Text] [Related]
2. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
3. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer.
Sánchez-Carbayo M; Urrutia M; Silva JM; Romaní R; De Buitrago JM; Navajo JA
J Urol; 2001 May; 165(5):1462-7. PubMed ID: 11342897
[TBL] [Abstract][Full Text] [Related]
4. [Cytokeratins (UBC and CYFRA 21-1) and nuclear matrix proteins (NMP22) as urine tumor markers in the diagnosis of bladder cancer].
Sánchez-Carbayo M; Urrutia M; Hernández-Cerceño ML; González de Buitrago JM; Navajo JA
Med Clin (Barc); 2000 Mar; 114(10):361-6. PubMed ID: 10786344
[TBL] [Abstract][Full Text] [Related]
5. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence.
Boman H; Hedelin H; Holmäng S
J Urol; 2002 Jan; 167(1):80-3. PubMed ID: 11743280
[TBL] [Abstract][Full Text] [Related]
6. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors.
Giannopoulos A; Manousakas T; Gounari A; Constantinides C; Choremi-Papadopoulou H; Dimopoulos C
J Urol; 2001 Aug; 166(2):470-5. PubMed ID: 11458049
[TBL] [Abstract][Full Text] [Related]
7. Serial urinary IL-2, IL-6, IL-8, TNFalpha, UBC, CYFRA 21-1 and NMP22 during follow-up of patients with bladder cancer receiving intravesical BCG.
Sanchez-Carbayo M; Urrutia M; Romani R; Herrero M; Gonzalez de Buitrago JM; Navajo JA
Anticancer Res; 2001; 21(4B):3041-7. PubMed ID: 11712808
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder.
Kibar Y; Goktas S; Kilic S; Yaman H; Onguru O; Peker AF
Ann Clin Lab Sci; 2006; 36(1):31-8. PubMed ID: 16501234
[TBL] [Abstract][Full Text] [Related]
9. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder.
Shariat SF; Herman MP; Casella R; Lotan Y; Karam JA; Stenman UH
Eur Urol; 2005 Sep; 48(3):424-31. PubMed ID: 15963628
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma.
Gkialas I; Papadopoulos G; Iordanidou L; Stathouros G; Tzavara C; Gregorakis A; Lykourinas M
Urology; 2008 Nov; 72(5):1159-63. PubMed ID: 18514770
[TBL] [Abstract][Full Text] [Related]
11. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.
Svatek RS; Herman MP; Lotan Y; Casella R; Hsieh JT; Sagalowsky AI; Shariat SF
Cancer; 2006 Apr; 106(8):1701-7. PubMed ID: 16541433
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of urinary NMP22 to detect tumor recurrence of superficial bladder cancer after transurethral resection.
Miyanaga N; Akaza H; Tsukamoto S; Shimazui T; Ohtani M; Ishikawa S; Noguchi R; Manabe F; Nishijima Y; Kikuchi K; Sato K; Hayashi H; Kondo F; Shiraiwa H; Aoyama O
Int J Clin Oncol; 2003 Dec; 8(6):369-73. PubMed ID: 14663639
[TBL] [Abstract][Full Text] [Related]
13. Comparative sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, tissue polypeptide antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer.
Sánchez-Carbayo M; Herrero E; Megías J; Mira A; Soria F
J Urol; 1999 Dec; 162(6):1951-6. PubMed ID: 10569545
[TBL] [Abstract][Full Text] [Related]
14. NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer.
Zippe C; Pandrangi L; Potts JM; Kursh E; Novick A; Agarwal A
Anticancer Res; 1999; 19(4A):2621-3. PubMed ID: 10470205
[TBL] [Abstract][Full Text] [Related]
15. Comparison of BTA stat and NMP22 tests in the detection of bladder cancer.
Oge O; Atsü N; Sahin A; Ozen H
Scand J Urol Nephrol; 2000 Dec; 34(6):349-51. PubMed ID: 11195897
[TBL] [Abstract][Full Text] [Related]
16. Comparison of nuclear matrix protein 22 and bladder tumor antigen in urine of patients with bladder cancer.
Abbate I; D'Introno A; Cardo G; Marano A; Addabbo L; Musci MD; Pagliarulo A; Correale M; Quaranta M
Anticancer Res; 1998; 18(5B):3803-5. PubMed ID: 9854500
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--NMP22 as a urinary marker for surveillance of bladder cancer. NMP22 Study Group].
Akaza H; Miyanaga N; Tsukamoto T; Ishikawa S; Noguchi R; Ohtani M; Kawabe K; Kubota Y; Fujita K; Obata K; Hirao Y; Kotake T; Ohmori H; Kumazawa J; Koiso K
Gan To Kagaku Ryoho; 1997 May; 24(7):829-36. PubMed ID: 9170521
[TBL] [Abstract][Full Text] [Related]
18. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer.
Zippe C; Pandrangi L; Agarwal A
J Urol; 1999 Jan; 161(1):62-5. PubMed ID: 10037369
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma.
Nisman B; Barak V; Shapiro A; Golijanin D; Peretz T; Pode D
Cancer; 2002 Jun; 94(11):2914-22. PubMed ID: 12115379
[TBL] [Abstract][Full Text] [Related]
20. [The usefulness of urinary FDP in the diagnosis of bladder cancer: comparison with NMP22, BTA and cytology].
Oeda T; Manabe D
Nihon Hinyokika Gakkai Zasshi; 2001 Jan; 92(1):1-5. PubMed ID: 11235137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
